Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm

Xtandi (Enzalutamide) – Second Generation Androgen Receptor (AR) Signalling Inhibitor

Implications for Astellas as Medivation Invites Offers

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of 2017 seeing sales decline, this situation was worrying for both <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091:1">Astellas Pharma Inc (4503 JP)</a> and its new US partner <a href="https://www.smartkarma.com/entities/1131" target="_blank" data-smartkarma-citation="entities:1131:1">Pfizer (PFE US)</a>, which had only recently spent US$11 billion on buying Medivation, to get access to Xtandi. More recently, Xtandi’s big rival – <a href="https://www.smartkarma.com/entities/1132" target="_blank" data-smartkarma-citation="entities:1132:1">Johnson &amp; Johnson's (JNJ US)</a>Zytiga – had also performed well in data presented at ASCO in…

For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of 2017 seeing sales decline, this situation was worrying for both Astellas Pharma Inc (4503 JP) and its new US partner Pfizer (PFE US), which had only recently spent US$11 billion on buying Medivation, to get access to Xtandi. More recently, Xtandi’s big rival – Johnson &amp; Johnson's (JNJ US)Zytiga – had also performed well in data presented at ASCO in…

Astellas (4503) - PROSPER Data Revives Value Story